Glenon v. Abbott Laboratories

District Court, S.D. California·Decided September 18, 2023·No. 3:22-cv-02061·Unknown

Opinion

DJ GLENON, individually and on behalf Case No.: 22-cv-2061-AGS-DEB of others similarly situated, ORDER DENYING DEFENDANT’S Plaintiff, v. AMENDED COMPLAINT (ECF 14)

ABBOTT LABORATORIES, Defendant.

In this putative class action, plaintiff alleges that defendant Abbott Laboratories disclosed medical information about him and hundreds of other patients in a mass email. Abbott moves to dismiss. BACKGROUND1 In 2022, Synovation Medical Group shared with defendant Abbott Laboratories a patient list of 375 chronic-pain patients. (ECF 11, at 4; ECF 19, at 8.) Abbott sent a group email to those patients—including plaintiff DJ Glenon—that revealed all the recipients’ email addresses. (ECF 11, at 4.) In addition, Glenon alleges that the email, excerpted below, implicitly exposed his chronic-pain condition and his health-care provider: Hello!

Synovation Medical Group is welcoming a new physician . . . and he is offering an education event on November 2nd from 12-1pm. You are receiving this email because the topic addresses pain therapies that could help you. 25

1 For motion-to-dismiss purposes, this Court accepts “the factual allegations in the complaint as true” and construes them “in the light most favorable to the plaintiff.” (ECF 19, at 8.) The attached flyer was titled “Abbott’s Advancements in Chronic Pain Relief,” and it touted a “treatment for chronic pain” for those who have “tried multiple treatments for chronic pain but have not yet found effective pain relief.” (ECF 19-1, at 2.) Glenon sued Abbott for violating California’s Confidentiality of Medical Information Act and sought class certification. Abbott moves to dismiss the amended complaint for failing to state a claim. To survive such a motion, a complaint must contain enough facts to “state a claim to relief that is plausible on its face.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009); see also Fed. R. Civ. P. 12(b)(6). Facial plausibility requires more than mere “conclusions” or a “formulaic recitation” of elements; it must be based on “factual allegations” that “raise a right to relief above the speculative level.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007) (cleaned up). Under the Confidentiality of Medical Information Act, certain covered entities “shall not disclose medical information regarding a patient . . . without first obtaining an authorization.” Cal. Civ. Code § 56.10(a). Abbott protests that Glenon has not plausibly alleged (1) “that Abbott disclosed protected ‘medical information,’” (2) “that Abbott is the type of entity covered” by the CMIA, or (3) “that Abbott acted negligently.” (ECF 14-1, at 13.) A. Medical Information First, Abbott argues that its mass email did not divulge “medical information” under the CMIA, as it did not include (a) individually identifiable information, nor (b) any prohibited medical topics. See Cal. Civ. Code § 56.05(i) (defining “medical information”). As to the former point, Abbott disputes that Glenon’s email address constituted “individually identifiable” information. But the CMIA’s definition of that term seems to categorically include email addresses: “Individually identifiable” means that the medical information includes or contains any element of personal identifying information sufficient to allow identification of the individual, such as the patient’s name, address, electronic mail address, telephone number, or social security number, or other information that, alone or in combination with other publicly available information, reveals the identity of the individual. Cal. Civ. Code § 56.05(i) (emphasis added). Yet in Abbott’s view, the CMIA does not protect email addresses unless they are independently shown to be “sufficient to allow identification of the individual.” (ECF 14-1, at 17.) Glenon’s email address doesn’t qualify, according to Abbott, because it “did not include Plaintiff’s name” or other telling details. (Id. at 17 n.10; see also id. at 17 (arguing that “cryptic email addresses . . . are insufficient to identify their owner”).) This reading would lead to absurd results: Glenon might need to live on “DJ Glenon Street” to invoke the CMIA’s protection of home addresses. Or he might have to change his phone number to “(800) D-GLENON” to ensure the CMIA shielded it from disclosure. At any rate, the rule against surplusage dispenses with this argument. Courts must make “every effort not to interpret a provision in a manner that renders other provisions of the same statute . . . meaningless or superfluous.” United States v. Neal, 776 F.3d 645, 652 (9th Cir. 2015). If the phrase “sufficient to allow identification of the individual” was an implied further test for every item in the definitional list, the qualifier for the last item— “other information that . . . reveals the identity of the individual”—would become redundant and superfluous.2 See Cal. Civ. Code § 56.05(i) (emphasis added). Thus, Glenon’s email address is entitled to CMIA protection without an individualized inquiry. As to Abbott’s other point, in the light most favorable to Glenon, the mass email plausibly released prohibited medical content, such as his “medical history,” “physical condition, or treatment.” See Cal. Civ. Code § 56.05(i). It begins, “You are receiving this email because the topic addresses pain therapies that could help you.” (ECF 19, at 8

Free access — add to your briefcase to read the full text and ask questions with AI

Glenon v. Abbott Laboratories, (S.D. Cal. 2023).

Glenon v. Abbott Laboratories (Glenon v. Abbott Laboratories) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Raich v. Gonzales
500 F.3d 850 (Ninth Circuit, 2007)
United States v. Denard Neal
776 F.3d 645 (Ninth Circuit, 2015)